218457-67-1
中文名稱
6-[4-(叔丁基)苯氧基]吡啶-3-胺
英文名稱
5-AMINO-2-(4-TERT-BUTYLPHENOXY)PYRIDINE
CAS
218457-67-1
分子式
C15H18N2O
MDL 編號(hào)
MFCD00052647
分子量
242.32
MOL 文件
218457-67-1.mol
更新日期
2025/03/12 10:54:43
218457-67-1 結(jié)構(gòu)式
基本信息
中文別名
6-[4-(叔丁基)苯氧基]吡啶-3-胺 英文別名
5-AMINO-2-(4-TERT-BUTYLPHENOXY)PYRIDINE6-[4-(TERT-BUTYL)PHENOXY]PYRIDIN-3-AMINE
BUTTPARK 96\12-100
所屬類別
醫(yī)藥中間體：吡啶類化合物物理化學(xué)性質(zhì)
熔點(diǎn)89-90
儲(chǔ)存條件2-8°C
溶解度溶于 DMSO (>30 mg/ml)
形態(tài)固體
顏色灰白色至淡橙色
穩(wěn)定性可在-20°C下的DMSO中的溶液儲(chǔ)存長達(dá)3個(gè)月。
CAS 數(shù)據(jù)庫218457-67-1(CAS DataBase Reference)
安全數(shù)據(jù)
警示詞警告
危險(xiǎn)性描述H302-H315-H319-H335
防范說明P271-P261-P280
危險(xiǎn)品標(biāo)志Xi
Hazard NoteIrritant
海關(guān)編碼2933399990
6-[4-(叔丁基)苯氧基]吡啶-3-胺價(jià)格(試劑級(jí))
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2025/02/08 | HY-135145 | 6-[4-(叔丁基)苯氧基]吡啶-3-胺 Limantrafin | 218457-67-1 | 5 mg | 312元 |
| 2025/02/08 | HY-135145 | 6-[4-(叔丁基)苯氧基]吡啶-3-胺 Limantrafin | 218457-67-1 | 10 mg | 500元 |
| 2025/02/08 | HY-135145 | 6-[4-(叔丁基)苯氧基]吡啶-3-胺 Limantrafin | 218457-67-1 | 10 mM * 1 mLin DMSO | 550元 |
常見問題列表
生物活性
CB-103 是一種口服活性的 Notch 轉(zhuǎn)錄激活復(fù)合物的抑制劑。CB-103 可在果蠅和小鼠中產(chǎn)生Notch功能喪失的表型，并抑制人類乳腺癌和白血病異種移植瘤的生長。靶點(diǎn)
| Target | Value |
|
Notch
() |
體外研究
CB-103 acts as a pan-NOTCH inhibitor by targeting NOTCH transcriptional activation complex.
CB-103 has shown the ability to block NOTCH signaling in human T cell acute lymphoblastic leukemia cancer cell lines.
CB-103 exhibits anti-tumor efficacy in GSI resistant T-ALL cell lines.
Cell Viability Assay
| Cell Line: | RPMI 8402, KOPTK1, PANC1, nRas driven melanoma cells |
| Concentration: | 10 μM |
| Incubation Time: | 4 days, 6 days |
| Result: | Caused a significant reduction in their growth potential. |
體內(nèi)研究
CB-103 inhibits NOTCH dependent cellular processes in mice.
CB-103 blocks in vivo growth of PDX models of T-ALL.
CB-103 (25 mg/kg; i.p./p.o.; 2x daily; for 2 weeks) inhibits growth of GSI/Mab resistant triple negative breast cancer.
CB-103 exhibits anti-tumor activity in xenograft models of human T-ALL and mouse mammary tumors.
| Animal Model: | NSG mice, triple negative breast cancer mouse xenograft model |
| Dosage: | 25 mg/kg |
| Administration: | Oral administration/Intraperitoneal injection; 2x daily; for 2 weeks |
| Result: | Inhibited growth of GSI/Mab resistant triple negative breast cancer. |